Literature DB >> 2121889

Interferon gamma is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin 2 infection.

G Karupiah1, R V Blanden, I A Ramshaw.   

Abstract

Athymic nude mice recover from an infection with recombinant vaccinia virus (VV) encoding murine interleukin 2 (IL-2), but treatment with a mAb to IL-2 accentuated infection. Administration of a mAb against interferon gamma (IFN-gamma) to mice infected with the IL-2-encoding virus completely prevented the IL-2-induced mechanisms of recovery. Both asialo-GM1+ (NK) and asialo-GM1- (non-NK) cells were participants in the IFN-gamma-mediated recovery of nude mice from infection with the IL-2-encoding VV recombinant. Depletion of asialo-GM1+ cells exacerbated infection, though not as much as anti-IFN-gamma mAb. In vitro, both asialo-GM1+ and asialo-GM1- nude mouse splenocytes produced IFN-gamma in response to IL-2.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121889      PMCID: PMC2188664          DOI: 10.1084/jem.172.5.1495

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  44 in total

1.  Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma.

Authors:  M R Kohonen-Corish; N J King; C E Woodhams; I A Ramshaw
Journal:  Eur J Immunol       Date:  1990-01       Impact factor: 5.532

2.  Effector and precursor phenotypes of lymphokine-activated killer cells in mice with severe combined immunodeficiency (scid) and athymic (nude) mice.

Authors:  M Hasui; Y Saikawa; M Miura; N Takano; Y Ueno; A Yachie; T Miyawaki; N Taniguchi
Journal:  Cell Immunol       Date:  1989-04-15       Impact factor: 4.868

3.  Target cell lysis by natural killer cells is influenced by beta 2-microglobulin expression.

Authors:  A Müllbacher; N J King
Journal:  Scand J Immunol       Date:  1989-07       Impact factor: 3.487

4.  Enhanced virus replication and inhibition of lymphocytic choriomeningitis virus disease in anti-gamma interferon-treated mice.

Authors:  T P Leist; M Eppler; R M Zinkernagel
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

5.  Cytotoxic T lymphocyte control of acute lymphocytic choriomeningitis virus infection: interferon gamma, but not tumour necrosis factor alpha, displays antiviral activity in vivo.

Authors:  L S Klavinskis; R Geckeler; M B Oldstone
Journal:  J Gen Virol       Date:  1989-12       Impact factor: 3.891

6.  Elevated natural killer cell responses in mice infected with recombinant vaccinia virus encoding murine IL-2.

Authors:  G Karupiah; B E Coupar; M E Andrew; D B Boyle; S M Phillips; A Müllbacher; R V Blanden; I A Ramshaw
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

7.  Cell-mediated immune responses to influenza virus antigens expressed by vaccinia virus recombinants.

Authors:  M E Andrew; B E Coupar; G L Ada; D B Boyle
Journal:  Microb Pathog       Date:  1986-10       Impact factor: 3.738

8.  Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice.

Authors:  M K Gately; T D Anderson; T J Hayes
Journal:  J Immunol       Date:  1988-07-01       Impact factor: 5.422

9.  Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia.

Authors:  D J Peace; M A Cheever
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

10.  Antiviral protection by virus-immune cytotoxic T cells: infected target cells are lysed before infectious virus progeny is assembled.

Authors:  R M Zinkernagel; A Althage
Journal:  J Exp Med       Date:  1977-03-01       Impact factor: 14.307

View more
  34 in total

1.  Poxvirus-encoded gamma interferon binding protein dampens the host immune response to infection.

Authors:  Isaac G Sakala; Geeta Chaudhri; R Mark Buller; Anthony A Nuara; Hongdong Bai; Nanhai Chen; Gunasegaran Karupiah
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

Review 2.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

3.  Construction and characterization of replication-competent simian immunodeficiency virus vectors that express gamma interferon.

Authors:  L D Giavedoni; T Yilma
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

4.  Gamma interferon is critical for resistance to Theiler's virus-induced demyelination.

Authors:  M Rodriguez; K Pavelko; R L Coffman
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  Importance of interferons in recovery from mousepox.

Authors:  G Karupiah; T N Fredrickson; K L Holmes; L H Khairallah; R M Buller
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

6.  Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways.

Authors:  L G Guidotti; S Guilhot; F V Chisari
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity In vivo.

Authors:  S Mahalingam; J M Farber; G Karupiah
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Effects of virally expressed interleukin-10 on vaccinia virus infection in mice.

Authors:  M G Kurilla; S Swaminathan; R M Welsh; E Kieff; R R Brutkiewicz
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

9.  Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons.

Authors:  Mauro Pires Moraes; Teresa de Los Santos; Marla Koster; Traci Turecek; He Wang; Vladimir G Andreyev; Marvin J Grubman
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

10.  Gamma interferon levels during Chlamydia trachomatis pneumonia in mice.

Authors:  D M Williams; B G Grubbs; J Schachter; D M Magee
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.